Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 82, 102418
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 14 references indexed in Scilit:
- How we manage Gaucher Disease in the era of choicesBritish Journal of Haematology, 2018
- Recent advances and future challenges in Gaucher diseaseBlood Cells, Molecules, and Diseases, 2018
- Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imigluceraseAmerican Journal of Hematology, 2016
- Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher diseaseAmerican Journal of Hematology, 2016
- Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United StatesMolecular Genetics and Metabolism, 2016
- Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher DiseasePLOS ONE, 2015
- First plant-made biologic approvedNature Biotechnology, 2012
- Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher diseaseBlood, 2011
- A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I InvestigationPLOS ONE, 2009
- Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell systemPlant Biotechnology Journal, 2007